تافعاضلماو تايفولل اًيسيئر اًببس مدلا يف تافسوفلا عافترا ربتعي ةليوط ةدم ذنم تتبث دقلو .نمزلما يولكلا روصقلا ىضرم دنع ضارمأ نم ةافولا رطخ ةدايزو مدلاب تافسوفلا عافترا ينب ام ةقلاعلا حملالما ةلاقلما هذه ضرعتست .يئاعولا سلكتلاو ةيئاعولا بلقلا اهتحضوأ امك ةيئاعولا تاسلكتلل ةيضارملإا ةيلمعلل ةديدلجا يف روفسوفلل زيملما يميظنتلا رودلا ةًرهظم ةثيدلحا ثوحبلا ةيللآا هذه .ةيومدلا ةيعولأل ءاسللما ةيلضعلا ايل...

Fibroblastic growth factor 23 (FGF23) regulates renal phosphate reabsorption and 1alpha-hydroxylase activity. Ablation of FGF23 results in elevated serum phosphate, calcium, and 1,25-dihydroxyvitamin D3 [1,25(OH)(2)D] levels; vascular calcifications; and early death. For determination of the independent roles of hyperphosphatemia and excess vitamin D activity on the observed phenotypic abnormal...

BACKGROUND Hyperphosphatemia is a common problem in patients with kidney failure. It is usually mild and rarely severe enough to cause metabolic acidosis on its own. Besides kidney failure, use of phosphate containing enemas, rhabdomyolysis, and tumor lysis syndrome are common causes of severe hyperphosphatemia. CASE REPORT A 74-year-old man with a history of diabetes mellitus type II, arterial...

Elevated serum phosphorus is associated with higher death risk in hemodialysis patients. Previous studies have suggested that both higher serum parathyroid hormone (PTH) level and higher dietary protein intake may contribute to higher serum phosphorus levels. However, it is not well known how these two factors simultaneously contribute to the combined risk of hyperphosphatemia in real patient-c...

Hyperphosphatemia has been associated with adverse outcomes in patients with end stage kidney disease (ESKD). The purpose of this study was to determine risk factors for hyperphosphatemia in ESKD patients treated with peritoneal dialysis (PD). This information will be used to develop a patient specific phosphate binder application to facilitate patient self-management of serum phosphate. Adult ...

Treatments for hyperphosphatemia in hypoparathyroidism were identified as a low-phosphorus diet, phosphate binders, diuretics, and parathyroid hormone replacement (PTH 1-34 and PTH 184). The treatments that have proven considerable promise for the hypoparathyroid patient were the parathyroid hormone replacement therapies. The author recommended PTH 1-84 as the mainstay of hormone replacement th...

Hyperphosphatemia is a major cause of morbidity and mortality in patients with chronic kidney disease. The association between hyperphosphatemia and increased risk of death from cardiovascular disease/vascular calcification has been well established for a long time. This review explores the new aspects of pathogenesis of vascular calcification, as demonstrated by recent advances showing a recog...

pruritus is a common and bothersome problem among uremic patients which negatively affects life quality and prognosis of the patient. various factors are known to be involved in the development of pruritus. the aim of this study was to assess the frequency and the factors which may have relationship with uremic pruritus, especially bone mineral metabolism indicators. current cross-sectional stu...

Aims: To describe the characteristics of chronic kidney disease patients with hyperphosphatemia before dialysis. To assess the impact of pre-dialysis hyperphosphatemia on dialysis mortality. Methods: All patients beginning a dialysis treatment in 2005-2006 in all the nephrology units operating in the Lorraine region of northeastern France were considered. Among them, those who were referred to ...

INTRODUCTION Phosphate level is often deranged during acute illness, regardless of the presence of kidney injury or not. A few studies described that hypophosphatemia may associated with outcome in patients admitted to the burn unit, but the literatures for hyperphosphatemia is limited. Our study aims to evaluate if hyperphosphatemia, one of the sign of severe tissue damage or kidney injury, wi...